NCT01656161View on ClinicalTrials.gov

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Triptorelin embonate 22.5 mg

Trial Locations (10)

1475

East Rand Urology Research Unit, Clinix Private Clinic, Johannesburg

1619

Clinresco Centres (Pty) Ltd, Kempton Park

2571

Wilmed Park Hospital, Klerksdorp

6530

JCM Bahlmann, George

7130

Vergelegen Medi-Clinic, Somerset West

7505

Department of Urology, Tygerberg Hospital, Tygerberg

7646

Paarl Medical Centre, Paarl

7925

New Groote Schuur Hospital, Division of Urology, Cape Town

0002

Clinical Trial Unit, Room 2-54, Prinshof Medical Campus, Pretoria

0028

Pretoria Urology Hospital, Pretoria

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Debiopharm International SA

INDUSTRY